Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 10, keine Gesamtzahl für „should“
Suchtreffer
Begriffe & Kennungen
Cresemba · 4.5 · (UGT inhibition) Prednisone Prednisolone (active metabolite): Co-administration should be (CYP3A4 substrate) A
Eintrag öffnenCrysvita · 4.5 · Caution should be exercised when combining burosumab with calcimimetic medicinal products (i.e. agents that mi
Eintrag öffnenCymbalta · 4.3 · Cymbalta should not be used in combination with fluvoxamine, ciprofloxacin or enoxacin (i.e. potent CYP1A2 inh
Eintrag öffnenCymbalta · 4.5 · Anticoagulants and antiplatelet agents: Caution should be exercised when duloxetine is combined with oral anti
Eintrag öffnenCymbalta · 4.5 · Monoamine oxidase inhibitors (MAOIs): Due to the risk of serotonin syndrome, duloxetine should not be used in
Eintrag öffnenDacogen · 4.8 · Haematological adverse drug reactions should be managed by routine monitoring of complete blood counts and ear
Eintrag öffnenDarunavir Krka · 4.5 · 17 associated with these agents. Caution should be exercised when combining one of these antineoplastic agents
Eintrag öffnenDarunavir Krka · 4.5 · 51 ANTIFUNGALS Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be plasma concentratio
Eintrag öffnenDarunavir Viatris (previously Darunavir Mylan) · 4.5 · Patients using oestrogens as hormone replacement therapy should be clinically monitored for signs of oestrogen
Eintrag öffnenDeferasirox Accord · 4.5 · 11 deferasirox with repaglinide should be avoided. If the combination appears necessary, careful clinical and
Eintrag öffnenDelstrigo · 4.5 · Delstrigo is a complete regimen for the treatment of HIV-1 infection; therefore, Delstrigo should not be admin
Eintrag öffnenDescovy · 4.5 · Descovy should not be administered concomitantly with medicinal products containing tenofovir alafenamide, ten
Eintrag öffnenDescovy · 4.5 · Descovy should not be administered concomitantly with medicinal products containing tenofovir alafenamide, ten
Eintrag öffnenDexdor · 4.5 · The possibility of enhanced hypotensive and bradycardic effects should be considered in patients receiving oth
Eintrag öffnenDexdor · 4.8 · Clinically significant hypotension or bradycardia should be treated as described in section 4.4.
Eintrag öffnenDiacomit · 4.5 · Co-administration with CYP3A4 substrates with a narrow therapeutic index should be avoided due to the markedly
Eintrag öffnenDiacomit · 4.5 · Co-administration with CYP3A4 substrates with a narrow therapeutic index should be avoided due to the markedly
Eintrag öffnenDiacomit · 4.5 · Co-administration with CYP3A4 substrates with a narrow therapeutic index should be avoided due to the markedly
Eintrag öffnenDiacomit · 4.5 · Co-administration with CYP3A4 substrates with a narrow therapeutic index should be avoided due to the markedly
Eintrag öffnenDiacomit · 4.5 · In the absence of available clinical data, caution should be taken with the following clinically relevant inte
Eintrag öffnen